Destiny Pharma Shares Decline Despite Positive XF-73 MRSA Data

August 05, 2024 12:53 PM BST | By Team Kalkine Media
 Destiny Pharma Shares Decline Despite Positive XF-73 MRSA Data
Image source: Shutterstock

XF-73 Data Announced

Destiny Pharma PLC (LSE:DEST) announced promising results for its lead drug, exeporfinium chloride, branded as XF-73, on Monday. The Brighton-based clinical-stage biotechnology company revealed data from a recent study indicating that XF-73 reduced MRSA infection in burn wound tissue by up to 99.99% compared to a placebo treatment. This study demonstrated the drug's effectiveness following a single topical application of 25, 50, or 100 micrograms of XF-73.

Significance of MRSA Reduction

MRSA, or methicillin-resistant Staphylococcus aureus, is a dangerous pathogen known for causing severe infections and potentially life-threatening sepsis with a high mortality rate. The results from the study are seen as a significant advancement in the development of XF-73, highlighting its potential to substantially reduce or eliminate MRSA from wound sites, thereby minimizing the risk of sepsis.

Chief Scientific Officer Bill Love commented on the study's results, stating that the data from the in vivo burn wound infection model provides compelling evidence of XF-73’s capability to significantly mitigate the risk of MRSA reaching the bloodstream and causing severe infections. This outcome is considered a key milestone for the continued development of XF-73 as a dermal product.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next